448 completed, 110 terminated, 82 unknown, 60 recruiting. 183 Phase 2, 151 Phase 3, 127 Not applicable, 82 Phase 1, 68 Phase 4.
Follow Crohn's Disease: new trials by email Literature Review of Crohn's Disease trials Research Report on Crohn's Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ACT for Veterans With IBD and Mental Health Challenges Acceptance and Commitment Therapy - Inflammatory Bowel Diseases, Crohn's Disease | Not applicable | Not yet recruiting | VA Office of Research and Development | 50 | 2028-01-01 | 2026-02-09 |
| Digital Mind Body Intervention Among Black and Hispanic Patients Living With Inflammatory Bowel Disease Digital Mind Body Intervention mobile application - Crohn's Disease, Ulcerative Colitis | Not applicable | Not yet recruiting | Montefiore Medical Center | 40 | 2027-07-01 | 2026-09-14 |
| MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease Mirikizumab, Fistula Tract Curettage and Closure - Crohn's Disease, Perianal Fistula | Phase 4 | Not yet recruiting | Icahn School of Medicine at Mount Sinai | 50 | 2026-12-01 | 2026-08-24 |
| Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease Inflammatory Bowel Disease, Crohn's Disease | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 100 | 2026-10-27 | 2026-10-22 | |
| A Study of SL-325 in Crohn's Disease Patients SL-325, Placebo - Crohn's Disease | Phase 2 | Not yet recruiting | Shattuck Labs, Inc. | 232 | 2026-10-01 | 2026-08-12 |
| Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi® TyboWe® Adalimumab Injection - Crohn's Disease | Phase 4 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 50 | 2026-09-23 | 2026-09-24 |
| A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease No intervention - Ulcerative Colitis, Crohn's Disease | Withdrawn | Takeda | 2026-09-21 | 2026-10-15 | ||
| Intertriginous/Periorificial Dermatoses in Patients With IBD on Anti-TNFα: Relative Abundance of Staphylococcus Aureus Within the Lesion Microbiota and Clinical Correlation (micSPIDER). Inflammatory Bowel Diseases, Crohn's Disease | Not yet recruiting | Centre Hospitalier Universitaire de Nīmes | 82 | 2026-09-01 | 2026-09-10 | |
| A Phase 1 Study of ATORM-C in Patients With Crohn's Disease Autologous Adult Stem Cell-Derived Intestinal Organoid - Crohn's Diseases, Crohn's Disease | Phase 1 | Recruiting | ORGANOIDSCIENCES LTD. | 18 | 2026-09-01 | 2026-09-16 |
| A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease Zasocitinib - Crohn's Disease | Phase 2 | Recruiting | Takeda | 20 | 2026-08-13 | 2026-08-24 |
| Online Pain Education for Crohn's Disease and Ulcerative Colitis Empowered Relief, Living Better with Chronic Pain - Crohn's Disease, Ulcerative Colitis (UC) | Not applicable | Not yet recruiting | Cedars-Sinai Medical Center | 60 | 2026-08-01 | 2026-08-27 |
| Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis Risankizumab, Trosunilimab, ABBV-701 - Crohn's Disease, Ulcerative Colitis | Phase 2 | Recruiting | AbbVie | 2000 | 2026-07-31 | 2026-10-20 |
| A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease H021 Enteric-coated Tablets Low-dose Group, H021 Enteric-coated Tablets High-dose Group, Placebo Group - Crohn's Disease | Phase 2 | Not yet recruiting | Jiangsu Carephar Pharmaceutical Co., Ltd. | 156 | 2026-07-12 | 2026-06-30 |
| Stopping PPI Therapy in Inactive IBD Continue PPI Therapy, Withdraw PPI Therapy - Ulcerative Colitis (UC), Crohn's Disease | Phase 4 | Recruiting | University of Nottingham | 80 | 2026-07-01 | 2026-07-08 |
| A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS) balinatunfib, balinatunfib-matching placebo - Colitis Ulcerative, Crohn's Disease | Phase 2 | Terminated | Sanofi | 7 | 2026-05-19 | 2026-10-22 |
| Real-World Study of IL-23 Inhibitors in Active Crohn's Disease IL-23 inhibitor, TNF inhibitors - Crohn's Disease | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 665 | 2026-04-16 | 2026-07-09 | |
| Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease Palmitoleic Acid + Infliximab, Infliximab - Crohn's Disease | Phase 4 | Not yet recruiting | Chinese Medical Association | 400 | 2026-04-01 | 2026-02-18 |
| A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting Crohn's Disease, Ulcerative Colitis | Completed | AbbVie | 1638 | 2026-02-09 | 2026-10-05 | |
| 68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease Ga68-FAPI-46 - Crohn's Disease, Intestinal Fibrosis | Early Phase 1 | Recruiting | Mayo Clinic | 45 | 2026-01-26 | 2026-02-09 |
| A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease Duvakitug, Placebo - Crohn's Disease | Phase 3 | Recruiting | Sanofi | 751 | 2026-01-22 | 2026-10-21 |
Showing 20 of 780. Sign in to see all of them.
Crohn Disease (780) · Colitis, Ulcerative (177) · Inflammatory Bowel Diseases (176) · Arthritis, Rheumatoid (27) · Inflammation (21) · Spondylitis, Ankylosing (17) · Arthritis, Psoriatic (14) · Psoriasis (14) · Digestive System Diseases (10) · Gastrointestinal Diseases (10) · Colitis (9) · Irritable Bowel Syndrome (9) · Intestinal Diseases (8) · Autoimmune Diseases (7) · Anxiety Disorders (6)
Gastroenteritis (774) · Intestinal Diseases (772) · Digestive System Diseases (770) · Gastrointestinal Diseases (770) · Inflammatory Bowel Diseases (604) · Colonic Diseases (187) · Colitis (175) · Pathological Conditions, Signs and Symptoms (73) · Pathologic Processes (42) · Musculoskeletal Diseases (36) · Immune System Diseases (35) · Joint Diseases (33) · Skin and Connective Tissue Diseases (32) · Arthritis (30) · Connective Tissue Diseases (30)
Infliximab (45) · Adalimumab (42) · Certolizumab Pegol (28) · vedolizumab (26) · Azathioprine (17) · Ustekinumab (13) · risankizumab (11) · Mesalamine (9) · Cholecalciferol (8) · Natalizumab (8) · mirikizumab (8) · upadacitinib (8) · Budesonide (7) · Methotrexate (7) · guselkumab (7)
AbbVie (37) · Takeda (36) · Abbott (14) · UCB Pharma (13) · GlaxoSmithKline (11) · Merck Sharp & Dohme LLC (11) · Biogen (10) · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (10) · Jinling Hospital, China (10) · Pfizer (10) · Assistance Publique - Hôpitaux de Paris (9) · AstraZeneca (9) · Janssen Research & Development, LLC (9) · Shire (9) · AbbVie (prior sponsor, Abbott) (8)
United States (344) · Canada (156) · France (141) · Germany (122) · Israel (118) · Belgium (112) · Poland (102) · United Kingdom (102) · Italy (100) · Netherlands (98) · Spain (96) · Czechia (83) · Hungary (79) · Australia (76) · Japan (76)
Arie Levine, MD (6) · Brian Bressler, MD (4)
PMID 37368103, PMID 29380251, PMID 40243391, PMID 26893500, PMID 30739254, PMID 36150926, PMID 37224198, PMID 27959607, PMID 29142515, PMID 29409871, PMID 29909019, PMID 31279870, PMID 32964215, PMID 34077627, PMID 34546360, PMID 35435862, PMID 37391056, PMID 38096402, PMID 38310565, PMID 38492903, PMID 38492904, PMID 38982567, PMID 39054592, PMID 39131711, PMID 39231444, PMID 39485390, PMID 40357993, PMID 41189093, PMID 41264726, PMID 41763462, PMID 42427284, PMID 16267322, PMID 17634466, PMID 18398081, PMID 19201775, PMID 22325170, PMID 22344964, PMID 22704916, PMID 23188075, PMID 24281461, PMID 25996351, PMID 28209624, PMID 28420280, PMID 28487349, PMID 29247068, PMID 29857145, PMID 29939254, PMID 30054164, PMID 30203005, PMID 30615117
2023 (17), 2017 (14), 2014 (11), 2015 (8), 2016 (6), 2019 (6), 2008 (5), 2018 (4), 2025 (3), 2005 (2), 1IK2RD000689-01A2 (1), 1UL1RR025014-01 (1), 2004 (1), 2009 (1), K12TR004411 (1)